Company intelligence / Profile preview
Nanjing Delova Biotech Co., Ltd.
Nanjing, Jiangsu, Chinaen.delovabio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- NDA
01
Overview
Delova Biotech’s lead product QP001 (Qamzova®, meloxicam injection) received FDA approval in April 2025 for moderate-to-severe pain management in adults. The company has nearly 10 non-opioid analgesics at various clinical development stages targeting unmet needs in both China and the US. Their platforms focus on improving drug delivery and efficacy of difficult-to-dissolve drugs with a strong emphasis on patent protection throughout the drug lifecycle.
- Therapeutic areas
- OtherRheumatologyNeurology
- Modalities
- Small moleculesSynthetic peptidesAntisense oligonucleotidesAptamersGene therapyRecombinant proteins
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Nanjing Delova Biotech Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing Delova Biotech Co., Ltd..